The efficacy of Bromfenac sodium after intravitreal injection of Ranibizumab for age-related macular degeneration

The efficacy of Bromfenac sodium after intravitreal injection of Ranibizumab for age-related macular degeneration - the efficacy of Bromfenac after injection of Ranibizumab for AMD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006573

Enrollment

Registered

2011-10-18

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

age-related macular degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: cases with age-related macular degeneration

Exclusion criteria

Exclusion criteria: subjects with systemic risk factors

Design outcomes

Primary

Measure	Time frame
visual acuity, fundus examination including FA, IA and optical coherence tomography(OCT) , number of intravitreal injection	—

Countries

Japan

Contacts

Public ContactShion Haneda

Yamagata University Hospital Department of Ophthalmology

Outcome results